The team at Johns Jacobs University in Johns Hopkins has developed a way of using a new technique called orthopysis that is similar to orthopedically guided surgery.
Orthopysic surgeons use a machine that allows them to bend or flex the knee to create a better “grip” on the joint, and to “bend the knee” so it moves freely.
The new technique, which is still in clinical trials, is a major advancement in orthopics and is being developed by Johns Hopkins’s Center for the Human Sciences.
Dr. John DeBruyn, director of the Johns Hopkins Center for Orthopics, said that while the procedure is still a relatively new development, the team is moving forward with it.
“This is an important advancement in our field and it is very promising,” he said.
The technique works in tandem with a technique called neuromuscular brace.
The concept is that the muscles of the knee flex and extend during the healing process, allowing the bone to heal better.
“The most important part of this is that it is a very safe, controlled procedure that is completely safe and does not pose any risks to the patient,” DeBruckyn said.
It takes a patient between six to 12 hours to recover from the procedure.
The team is testing the new technique in conjunction with the new clinical trials of a new technology called Orthotec.
Orthoteca, a joint-related technology, is currently in clinical trial at a number of hospitals.
“It is a technology that helps us to keep the knee as strong as possible, but also to avoid joint damage,” DeBuyn said of Orthotech.
“You are able to make the joint stronger without causing significant damage to the bone.”
Orthopy-based surgeries are common at Johns Johns Hopkins, but there are many other options available to the orthopedist, including mechanical ankle casts and robotic devices, which can also be used on the knee.
DeBrouyn said that the team plans to begin clinical trials with orthopedists at Johns Island Hospital in New York City and other hospitals later this year.
For now, however, the procedure will remain under wraps.
“We are going to have to wait for the clinical trial to determine what the actual results are going, but we believe that we are on the right track,” DeBroun said.